Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CLL
•
CML
•
Hematology
How would you treat CML and CLL that occurred together?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In patients with CML who are receiving 1st line TKI with good molecular response, are you continuing therapy or switching to asciminib based on the ASC4FIRST data?
Are there different strategies you would utilize to monitor and manage potential resistance in patients with CML receiving asciminib?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
Does ASC4FIRST data justify the use of first-line asciminib for all newly diagnosed CML over other TKIs, considering that the MMR difference was not significantly different, and post-progression survival data is not yet mature?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
